
COSCIENS BIOPHARMA CORP.
Share · CA22112H1010 · CSCI · A40J1L (XTSE)
3,14 EUR
11.06.2025 13:36
Current Prices from COSCIENS BIOPHARMA CORP.
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() NASDAQ |
CSCI
|
USD
|
11.06.2025 13:36
|
3,60 USD
| 3,54 USD
+1,69 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | -3,98 % | -2,05 % | 28,00 % | 13,20 % | -43,60 % | -41,29 % |
Company Profile for COSCIENS BIOPHARMA CORP. Share
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
Company Data
Name COSCIENS BIOPHARMA CORP.
Company COSCIENS Biopharma Inc.
Symbol CSCI
Website
https://www.cosciensbio.com
Primary Exchange
Frankfurt

WKN A40J1L
ISIN CA22112H1010
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.
Country Canada
Currency EUR
Employees 0,0 T
Address 222 Bay Street, M5K 1E7 Toronto
IPO Date 1996-07-18
ID Changes
Date | From | To |
---|---|---|
09.08.2024 | AEZS | CSCI |
01.07.2004 | AELA | AEZS |
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | ET8.F |
NASDAQ | CSCI |
More Shares
Investors who COSCIENS BIOPHARMA CORP. hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.